Home » Cancer Drug Developer Endocyte Drops Price for Initial Offering
Cancer Drug Developer Endocyte Drops Price for Initial Offering
Endocyte Inc., a developer of drugs for ovarian and lung tumors, cut the price for its initial public offering by as much as 53 percent.
Bloomberg
Bloomberg
Upcoming Events
-
07May
-
14May
-
30May